Smith+Nephew, has received FDA 510(k) clearance for its new CATALYSTEM Primary Hip System, designed to meet the evolving demands of primary hip surgery.

This includes the increased use of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs).

The system features advancements in primary hip arthroplasty, such as a shorter, proximally filling stem that facilitates easier preparation and insertion using the direct anterior approach.

This less invasive procedure may enhance patient recovery and range of motion, catering to diverse patient anatomies with a compound annual growth rate exceeding 10%.

Developed using global data sets on femoral morphologies, the CATALYSTEM system ensures a precise fit.

It incorporates a triple-taper stem design with uniform proximal loading, suitable for anterior and other surgical approaches due to its reduced distal stem geometry and shorter lengths.

The system’s benefits: “The CATALYSTEM facilitates accurate proximal fit without distal interference, ideal for my patients undergoing the direct anterior approach.

Its single modular tray design enhances efficiency, reducing shelf space and sterilization costs, which is particularly advantageous in ASC settings.”

The system also introduces ACCUBROACH◊ Technology, ensuring reproducibility between broach and implant placements for predictable and stable stem seating.

“ACCUBROACH Technology provides surgeons with confidence in achieving precise axial and rotational stability, ensuring optimal implant alignment.”

“The launch of the CATALYSTEM Primary Hip System complements hip portfolio, enhancing surgical precision and efficiency with our OXINIUM◊ Technology and robotics integration, to improve patient outcomes.”

 

 

 

Source: smith-nephew.com

Report Abuse